This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/chemspider/
n23http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/chebi/
n18http://www.drugs.com/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/wikipedia/
n21http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/pdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/pubchem-compound/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n25http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00148/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00148
rdf:type
n3:Drug
n3:description
An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine. [PubChem]
n3:generalReferences
# Burke DG, Chilibeck PD, Parise G, Tarnopolsky MA, Candow DG: Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab. 2003 Sep;13(3):294-302. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14669930 # Dangott B, Schultz E, Mozdziak PE: Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy. Int J Sports Med. 2000 Jan;21(1):13-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10683092 # Hespel P, Op't Eijnde B, Van Leemputte M, Urso B, Greenhaff PL, Labarque V, Dymarkowski S, Van Hecke P, Richter EA: Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. J Physiol. 2001 Oct 15;536(Pt 2):625-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11600695 # Hultman E, Soderlund K, Timmons JA, Cederblad G, Greenhaff PL: Muscle creatine loading in men. J Appl Physiol. 1996 Jul;81(1):232-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8828669 # Juhn M: Popular sports supplements and ergogenic aids. Sports Med. 2003;33(12):921-39. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12974658
n3:group
nutraceutical approved
n3:halfLife
3 hours
n3:indication
For nutritional supplementation, also for treating dietary shortage or imbalance
owl:sameAs
n20:DB00148 n21:DB00148
dcterms:title
Creatine
adms:identifier
n7:566 n8:DB00148 n9:16919 n10:586 n11:46504868 n12:PA164778930 n13:Creatine n14:C00300 n15:CRN
n3:mechanismOfAction
In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate. The reaction is catalysed by creatine kinase, and the result is phosphocreatine (PCr). Phosphocreatine binds with adenosine diphosphate to convert it back to ATP (adenosine triphosphate), an important cellular energy source for short term ATP needs prior to oxidative phosphorylation.
n3:packager
n24:271B4B75-363D-11E5-9242-09173F13E4C5 n24:271B4B73-363D-11E5-9242-09173F13E4C5 n24:271B4B74-363D-11E5-9242-09173F13E4C5
n3:synonym
Creatin (α-methylguanido)acetic acid N-Amidinosarcosine N-(aminoiminomethyl)-N-methylglycine N-[(e)-AMINO(imino)methyl]-N-methylglycine Methylglycocyamine Kreatin ((amino(Imino)methyl)(methyl)amino)acetic acid N-Methyl-N-guanylglycine (N-methylcarbamimidamido)acetic acid (alpha-Methylguanido)acetic acid N-Carbamimidoyl-N-methylglycine Creatine alpha-Methylguanidino acetic acid
n3:synthesisReference
Stefan Weiss, Helmut Krommer, "Process for the preparation of a creatine or creatine monohydrate." U.S. Patent US5719319, issued September, 1963.
n22:hasConcept
n23:M0005292
foaf:page
n18:creatine.html n25:cre_0086.shtml
n3:IUPAC-Name
n4:271B4B7D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B83-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B82-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B7F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B80-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B81-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B93-363D-11E5-9242-09173F13E4C5 n4:271B4B7B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B95-363D-11E5-9242-09173F13E4C5 n4:271B4B79-363D-11E5-9242-09173F13E4C5 n4:271B4B7C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B7A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4B89-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B8A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B84-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B85-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B87-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B86-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B88-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
57-00-1
n3:category
n3:containedIn
n5:271B4B77-363D-11E5-9242-09173F13E4C5 n5:271B4B78-363D-11E5-9242-09173F13E4C5 n5:271B4B76-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B8F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B91-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B92-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B94-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B8E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B8D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B90-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B7E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B8B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B8C-363D-11E5-9242-09173F13E4C5